| Q88882800 | Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome |
| Q37529187 | Antiretroviral Treatment with Efavirenz Disrupts the Blood-Brain Barrier Integrity and Increases Stroke Severity. |
| Q90442125 | Benzophenone: a ubiquitous scaffold in medicinal chemistry |
| Q90482934 | Clinical Pharmacokinetics and Drug Interactions of Doravirine |
| Q35892563 | Clinically relevant drug-drug interactions between antiretrovirals and antifungals |
| Q39364925 | Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz. |
| Q37287727 | Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects |
| Q35156365 | Determination of 10-chloromethyl-11-demethyl-12-oxo-calanolide A in rat plasma using liquid chromatography-tandem mass spectrometry and its application to pharmacokinetics |
| Q35586639 | Development and validation of a high performance liquid chromatography method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel non-nucleoside reverse transcriptase inhibitor and its application to a pharmacokinetic study i |
| Q55317261 | Development of peptide inhibitors of HIV transmission. |
| Q35111456 | Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine |
| Q47560158 | Discovery of a semi-synthesized cyclolignan as a potent HIV-1 non-nucleoside reverse transcriptase inhibitor |
| Q41040182 | Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands. |
| Q51538858 | Drug-Induced Mitochondrial Toxicity. |
| Q47112253 | Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era. |
| Q48608254 | Effects of crystalline state and self-nanoemulsifying drug delivery system (SNEDDS) on oral bioavailability of the novel anti-HIV compound 6-benzyl-1-benzyloxymethyl-5-iodouracil in rats. |
| Q64056259 | Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial |
| Q41931716 | Elsulfavirine: First Global Approval |
| Q38792785 | Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India |
| Q37613039 | Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects |
| Q40050910 | Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin |
| Q40446339 | Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients |
| Q42050799 | Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity |
| Q39291813 | Indicators of HIV-risk resilience among men who have sex with men: a content analysis of online profiles |
| Q36571936 | Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations |
| Q92859255 | Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice |
| Q40105941 | Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections |
| Q92135854 | Neuropsychiatric and Neurocognitive Manifestations in HIV-Infected Children Treated With Efavirenz in South Africa-A Retrospective Case Series |
| Q92550561 | Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes |
| Q90748454 | Norovirus antivirals: Where are we now? |
| Q38789791 | Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses. |
| Q35929429 | Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Rever |
| Q35999174 | Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents |
| Q26752603 | Pharmacokinetic and Metabolic Characteristics of Herb-Derived Khellactone Derivatives, A Class of Anti-HIV and Anti-Hypertensive: A Review |
| Q34229948 | Questioning the HIV-AIDS Hypothesis: 30 Years of Dissent |
| Q88026433 | Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum |
| Q90220238 | Rilpivirine as a potential candidate for the treatment of HIV-associated neurocognitive disorders (HAND) |
| Q38214338 | Sex and gender influences on pharmacological response: an overview |
| Q38798541 | Structure-guided design of small-molecule therapeutics against RSV disease |
| Q97067041 | TDP-43 prevents retrotransposon activation in the Drosophila motor system through regulation of Dicer-2 activity |
| Q40308165 | Tenofovir prodrugs: similar but not the same |
| Q90274970 | The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic |
| Q94545376 | The characteristics of pretreatment HIV-1 drug resistance in western Yunnan, China |
| Q59352293 | The dawn of precision medicine in HIV: state of the art of pharmacotherapy |
| Q38510112 | The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics |
| Q38954109 | Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients |
| Q39579431 | Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care |
Search more.